News | August 08, 2025
Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The submission is supported by positive results from the Phase 3 AMPLIFY trial
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
cSCC is one of the most common cancers in the U.S. and globally
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Subscribe To Our Newsletter & Stay Updated
